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Abstract

Key Points

IMPORTANCE Despite guidelines endorsing oral rehydration therapy, intravenous fluids are
commonly administered to children with acute gastroenteritis in high-income countries.

Question What clinical features are
associated with intravenous rehydration
and hospitalization in children with

OBJECTIVE To identify factors associated with intravenous fluid administration and hospitalization

acute gastroenteritis?
Findings In this secondary analysis of 2

in children with acute gastroenteritis.

randomized clinical trials with 1846

DESIGN, SETTING, AND PARTICIPANTS This study is a planned secondary analysis of the Pediatric

children, independent variables

Emergency Research Canada (PERC) and Pediatric Emergency Care Applied Research Network

associated with intravenous rehydration

(PECARN) probiotic trials. Participants include children aged 3 to 48 months with 3 or more watery

included a higher clinical dehydration

stools in 24 hours between November 5, 2013, and April 7, 2017, for the PERC study and July 8, 2014,

score, care in the US relative to Canada,

and June 23, 2017, for the PECARN Study. Children were from 16 pediatric emergency departments

greater frequency and duration of

throughout Canada (6) and the US (10). Data were analyzed from November 2, 2018, to March

vomiting, prior intravenous rehydration,

16, 2021.

and lack of oral ondansetron. A higher
clinical dehydration score, care in the

EXPOSURES Sex, age, preceding health care visit, distance between home and hospital, country

US, greater frequency of vomiting, and

(US vs Canada), frequency and duration of vomiting and diarrhea, presence of fever, Clinical

lack of oral ondansetron were

Dehydration Scale score, oral ondansetron followed by oral rehydration therapy, and

associated with hospitalization.

infectious agent.

Meaning These findings suggest that
oral ondansetron may support oral

MAIN OUTCOMES AND MEASURES Intravenous fluid administration and hospitalization.

rehydration therapy to reduce
intravenous rehydration and the

RESULTS This secondary analysis of 2 randomized clinical trials included 1846 children (mean [SD]
age, 19.1 [11.4] months; 1007 boys [54.6%]), of whom 534 of 1846 (28.9%) received oral

hospitalization of children with
gastroenteritis.

ondansetron, 240 of 1846 (13.0%) received intravenous rehydration, and 67 of 1846 (3.6%) were
hospitalized. The following were independently associated with intravenous rehydration: higher
Clinical Dehydration Scale score (mild to moderate vs none, odds ratio [OR], 8.73; 95% CI, 5.81-13.13;
and severe vs none, OR, 34.15; 95% CI, 13.45-86.73); country (US vs Canada, OR, 6.76; 95% CI, 3.1514.49); prior health care visit with intravenous fluids (OR, 4.55; 95% CI, 1.32-15.72); and frequency of
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Author affiliations and article information are
listed at the end of this article.

vomiting (per 5 episodes, OR, 1.66; 95% CI, 1.39-1.99). The following were independently associated
with hospitalization: higher Clinical Dehydration Scale score (mild to moderate vs none, OR, 11.10;
95% CI, 5.05-24.38; and severe vs none, OR, 23.55; 95% CI, 7.09-78.25) and country (US vs Canada,
OR, 3.37; 95% CI, 1.36-8.40). Oral ondansetron was associated with reduced odds of intravenous
rehydration (OR, 0.21; 95% CI, 0.13-0.32) and hospitalization (OR, 0.44; 95% CI, 0.21-0.89).
(continued)
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Abstract (continued)

CONCLUSIONS AND RELEVANCE Intravenous rehydration and hospitalization were associated
with clinical evidence of dehydration and lack of an oral ondansetron-supported oral rehydration
period. Strategies focusing on oral ondansetron administration followed by oral rehydration therapy
in children with dehydration may reduce the reliance on intravenous rehydration and hospitalization.
TRIAL REGISTRATION ClinicalTrials.gov Identifiers: NCT01853124 (PERC) and NCT01773967
(PECARN)
JAMA Network Open. 2021;4(4):e216433. doi:10.1001/jamanetworkopen.2021.6433

Introduction
Acute gastroenteritis (AGE) accounts for nearly 500 000 deaths in children younger than 5 years
annually.1 Although AGE is generally a mild, self-limited condition in high-income countries, it
accounts for almost 1.7 million emergency department (ED) visits2 and 60 000 hospitalizations
annually in the US.3 Guidelines uniformly support oral rehydration therapy (ORT), reserving
intravenous rehydration for children with severe dehydration.4-6 Unfortunately, clinical dehydration
scales have variable accuracy,7 and most overestimate dehydration severity in high-income
countries.8 These challenges, combined with the presence of vomiting, the need to minimize ED
length of stay, and caregiver expectations,9 often lead to intravenous rehydration use.10
Intravenous rehydration has potentially deleterious effects. Children rate intravenous insertion
as one of the most painful aspects of hospital care,11 influencing future reactions to painful events.12
Compared with ORT, intravenous rehydration is associated with phlebitis, longer hospital stays, and
major adverse events,13,14 and is one of the risk factors most strongly associated with ED revisits,
presumably because it reinforces the decision to seek ED care and reduces the educational focus on
ORT.15 Although quality improvement initiatives have been able to reduce intravenous rehydration
rates, in many institutions, use remains frequent.14,16 Thus, a better understanding of the factors
associated with intravenous rehydration is needed to identify approaches to mitigate use.
Reducing unnecessary hospitalizations is also a priority given cost considerations. In 2010, the
Agency for Healthcare Research and Quality estimated that the cost of preventable pediatric
hospitalizations for AGE in the US was nearly $150 million dollars.17 Although rotavirus vaccination
has reduced AGE hospitalizations by 36% globally,18 this enormous burden continues.19
Furthermore, there is considerable variation in hospitalization rates for AGE, and nonobjective
measures of dehydration may be an important driver.20
To address these issues, we conducted a secondary analysis of 2 large simultaneously collected
data sets. Our objective was to explore factors associated with intravenous rehydration and
hospitalization in children with AGE in the US and Canada.

Methods
Design
This study was a planned secondary analysis of the Pediatric Emergency Research Canada (PERC)
Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment (PROGUT) (trial protocol
available in Supplement 1)21,22 and Pediatric Emergency Care Applied Research Network (PECARN)
(trial protocol available in Supplement 2)23,24 randomized clinical trials of probiotics in children with
AGE-associated diarrhea. Research assistants at each site obtained written informed consent from
the children’s parents. Participants were enrolled between November 5, 2013, and June 23, 2017, in 1
of 16 EDs, 6 in the PERC trial and 10 in the PECARN trial. Research ethics board approval was
obtained at each site. The manuscript analysis plan for the present study is available in Supplement 3.
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This study followed the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) reporting guideline.

Participants
Eligible children were aged 3 to 48 months and had 3 or more watery stools reported in the
preceding 24 hours. Exclusion criteria were prior enrollment in the study, hematochezia, bilious
emesis, chronic gastrointestinal disease, structural heart disease, indwelling vascular access line,
immunotherapy or history of immunodeficiency, inability to be contacted for daily follow-up while
symptomatic, supplemental probiotic use in the preceding 14 days, clinical instability (eg,
hypovolemic shock), family member with an indwelling vascular access line, or being
immunocompromised.22,23 The main distinctions between the 2 studies were maximal symptom
duration before enrollment (72 hours in the PERC trial and 7 days in the PECARN trial) and different
investigational probiotic products. In addition, the PERC trial excluded children with pancreatic
dysfunction, oral or gastrointestinal surgery within the preceding 7 days, and known soy
hypersensitivity. Participants lost to follow-up in the primary clinical trials were eligible for inclusion
in this analysis if intravenous fluid administration status was known. The protocols for both trials
recommended ORT supported by ondansetron as needed but did not specify criteria for intravenous
rehydration or hospitalization.

Outcomes and Measurements
The primary outcomes, evaluated at the index visit, were (1) intravenous rehydration, defined as any
crystalloid administered through a peripheral intravenous line for the purposes of rehydration; and
(2) hospitalization, defined as admission to an inpatient unit outside the ED. We also collected
demographic characteristics, frequency of vomiting and diarrhea in the 24 hours pre-ED visit,
previous health care visit for the same illness, duration of illness, fever during the current illness
(temperature ⱖ38.0 °C at home or in the ED, adjusted to rectal temperature by adding 1.1 °C to the
axillary or 0.6 °C to the oral temperature25) or tactile temperature (PECARN), oral ondansetron, trial
of ORT, intravenous fluid administration, and ED disposition. Children who received oral ondansetron
within 30 minutes of ordering intravenous rehydration were not classified as having received oral
ondansetron to promote ORT.
A baseline modified Vesikari Scale score was calculated based on symptoms reported at the
index ED visit. The modified Vesikari Scale is a global gastroenteritis severity scale validated in our
population. Scores range from 0 to 20 and are categorized as mild (0-8), moderate (9-10), or severe
(ⱖ11).22,26 The number and duration of vomiting and diarrhea episodes were categorized according
to the modified Vesikari Scale score cut-points.22,26 Dehydration was assessed using the Clinical
Dehydration Scale (CDS), a validated 4-item instrument with high interrater reliability (κ = 0.77).7,27
The CDS includes an assessment of general appearance, eyes (eg, sunken), mucous membranes (eg,
dry), and tears. Total scores range from 0 to 8 and are grouped to correspond to dehydration
severity: none (0), mild to moderate (1-4), and severe (5-8).27 The CDS scores were assigned by a
trained research assistant at recruitment.

Laboratory Testing
Stool specimens were requested from all participants for enteropathogen identification. Testing was
performed using the Luminex xTAG Gastrointestinal Pathogen Panel (Luminex Corp)28 that tests for
viruses (adenovirus, norovirus, rotavirus), bacteria (Clostridioides difficile [formerly Clostridium]
toxins A and B, enterotoxigenic Escherichia coli heat-labile toxin and heat-stable toxin, E coli O157,
Salmonella, Shiga toxin-producing E coli, Shigella, Vibrio cholera, and Yersinia enterocolitica) and
parasites (Cryptosporidium, Entamoeba histolytica, and Giardia). Specimens collected in the PERC
study were also tested for adenovirus, astrovirus, norovirus, rotavirus, and sapovirus.29 Results were
unavailable at the time of disposition.
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Statistical Analysis
Demographic characteristics were combined from both trials and summarized with counts and
percentages for categorical data and medians and interquartile ranges for continuous data. Bivariate
analyses adjusted for site and multivariable analyses were used to explore the associations between
outcome variables (ie, intravenous rehydration and hospitalization) and the following prespecified,
biologically plausible covariates: sex, age in months using a priori determined groups (3 to <12
months, 12 to <24 months, 24 to <36 months, and 36 to <48 months), prior health care practitioner
visit during the current illness, country, distance to hospital, infectious agent, duration of vomiting
and diarrhea at the time of the index visit, frequency of vomiting and diarrheal episodes within 24
hours of the index visit, fever, ED CDS score, and oral ondansetron administration. Unadjusted
bivariate and adjusted multivariable odds ratios (ORs) and 95% CIs were obtained from generalized
mixed-effects logistic regression models that employed random intercepts and assumed a simple
diagonal covariance structure to adjust for clinical center.
We fit additional multivariable models in order to estimate the adjusted association of infectious
agents among the subset of participants from whom stool specimens were obtained. Infectious
agents were categorized as negative vs isolated virus vs isolated bacteria vs virus and bacteria
codetection vs parasites. In models assessing factors associated with hospitalization, the parasite
category was excluded owing to an insufficient number of hospitalized participants. Children 24
months or younger in whom C difficile was detected were classified as negative given the high
colonization rate and low likelihood of symptomatic causality. Finally, we fit additional multivariable
models to explore the separate associations of prior health care visits with and without intravenous
rehydration.
Data were analyzed using SAS/STAT software, version 9.4 (SAS Institute Inc). A type I error rate
of .05 was used to reject the null hypothesis of no association. All P values were 2-tailed. Data
analyses were conducted from November 2, 2018, to March 16, 2021.

Results
Participants
Of the 1857 participants randomized in the parent trials, we analyzed the results from 1846 children
(mean [SD] age, 19.1 [11.4] months; 1007 boys [54.6%]) (Figure 1). Table 1 and Table 2 summarize
demographic features. A total of 240 of 1846 participants (13.0%) received intravenous rehydration
at the index ED visit, and 67 of 1846 (3.6%) were hospitalized. Oral ondansetron to promote ORT
was administered to 534 of 1846 participants (28.9%): 166 of 876 (18.9%) in Canada and 368 of 970
(37.9%) in the US. When 3 or more vomiting episodes were reported, oral ondansetron was
administered to 408 of 892 participants (45.7%): 141 of 428 (32.9%) in Canada and 267 of 464
(57.5%) in the US.

Variables Associated With Intravenous Rehydration
In bivariate analysis adjusted for site (Table 1), variables associated with intravenous rehydration
included location of care in the US (167 of 970 [17.2%]); fever (161 of 981 [16.4%]); isolated virus (144
of 810 [17.8%]); parasites (4 of 19 [21.1%]); mild, moderate, or severe dehydration using the CDS
score (mild or moderate, 157 of 681 [23.1%]; severe, 27 of 40 [67.5%]); prolonged and more frequent
vomiting (ⱖ48 hours, prolonged, 101 of 504 [20.0%]; per 5-episode increase [more frequent] OR,
1.65; 95% CI, 1.44-1.89); more frequent diarrheal episodes (unadjusted OR, 1.41; 95% CI, 1.24-1.61 per
5-episode increase); prior health care visit with intravenous rehydration (11 of 16 [68.8%]); and
increased distance between home and the ED (unadjusted OR, 1.11; 95% CI, 1.02-1.19). Oral
ondansetron followed by ORT was associated with lower odds of intravenous rehydration (OR, 0.43;
95% CI, 0.31-0.61).
In the multivariable model, independent variables associated with intravenous rehydration
(Figure 2) were CDS scores indicative of mild to moderate (OR, 8.73; 95% CI, 5.81-13.13) and severe
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(OR, 34.15; 95% CI, 13.45-86.73) dehydration, care in the US (OR, 6.76; 95% CI, 3.15-14.49; relative to
Canada), detection of an isolated virus (OR, 1.80; 95% CI, 1.16-2.79; relative to negative), greater
number of vomiting episodes (OR, 1.66; 95% CI, 1.39-1.99 per 5-episode increase) and duration of
vomiting (OR, 2.53; 95% CI, 1.39-4.61 for ⱖ48 hours relative to no vomiting), and prior health care
visit (OR, 1.82; 95% CI, 1.20-2.77), particularly with intravenous rehydration (OR, 4.55; 95% CI, 1.3215.72). Oral ondansetron was associated with lower odds of intravenous rehydration (OR, 0.21; 95%
CI, 0.13-0.32).

Variables Associated With Hospitalization
In bivariate analysis adjusted for site (Table 2), the variables associated with hospitalization included
increased distance to the ED (US, OR, 1.23; 95% CI, 1.12-1.36), detection of an isolated viral
enteropathogen (OR, 2.89; 95% CI, 1.58-5.31), evidence of dehydration on the CDS score (severe,
OR, 53.45; 95% CI, 19.10-149.57), prolonged duration of vomiting (ⱖ48 hours, OR, 3.21; 95% CI,
1.37-7.56), greater frequency of diarrheal (OR, 1.67 per 5-episode increase; 95% CI, 1.39-2.01) and
vomiting episodes (OR, 1.50 per 5-episode increase; 95% CI, 1.25-1.81), prior health care practitioner
visit (yes, with rehydration, OR, 10.26; 95% CI, 3.11-33.86), and presence of a fever (OR, 1.93; 95%
CI, 1.14-3.28). Oral ondansetron followed by ORT was associated with lower odds of hospitalization
(OR, 0.47; 95% CI, 0.25-0.89).
In the multivariable model, independent variables associated with hospitalization (Figure 3)
included CDS scores indicative of mild to moderate (OR, 11.10; 95% CI, 5.05-24.38; P < .001) and
severe (OR, 23.55; 95% CI, 7.09-78.25; P < .001) dehydration, care in the US (OR, 3.37; 95% CI, 1.368.40 relative to Canada; P = .009), and greater number of vomiting (OR, 1.41; 95% CI, 1.13-1.77 per
5-episode increase; P = .003) and diarrhea (OR, 1.34; 95% CI, 1.07-1.68 per 5-episode increase;
P = .01) episodes. Administration of oral ondansetron was associated with a lower odds of
hospitalization (OR, 0.44; 95% CI, 0.21-0.89; P = .02).

Figure 1. Flow Diagram of Patients Analyzed from PERC and PECARN Cohorts
PERC cohort
2663 Children assessed
for eligibility

1777 Excluded
682 Met exclusion criteria
1049 Did not consent
46 Other reason

886 Underwent
randomization

10 Excluded because of missing IV
rehydration and hospitalization
data

PECARN cohort
3143 Children assessed
for eligibility

2172 Excluded
744 Met exclusion criteria
1155 Did not consent
11 Other reason

971 Underwent
randomization

1 Excluded from IV rehydration
analysis because of missing data
5 Excluded from hospitalization
analysis because of missing data

1846 Analyzed for IV rehydration
876 PERC
970 PECARN
1842 Analyzed for hospitalization
876 PERC
966 PECARN
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Table 1. Bivariate Analysis of Variables Associated With Emergency Department
Intravenous Fluid Administration
IV fluids during index ED visit, No./total No. (%)

Model results

No (n = 1606)

Yes (n = 240)

Unadjusted OR
(95% CI)a

Boys

878/1007 (87.2)

129/1007 (12.8)

1 [Reference]

Girls

727/838 (86.8)

111/838 (13.2)

1.03 (0.78-1.37)

Variable

P valueb

Sex
.82

Age group, mo
3.0 to <12.0

548/612 (89.5)

64/612 (10.5)

1 [Reference]

12.0 to <24.0

583/679 (85.9)

96/679 (14.1)

1.46 (1.03-2.06)

24.0 to <36.0

294/337 (87.2)

43/337 (12.8)

1.19 (0.78-1.81)

36.0 to <48.0

180/217 (82.9)

37/217 (17.1)

1.74 (1.11-2.72)

Canada

803/876 (91.7)

73/876 (8.3)

1 [Reference]

US

803/970 (82.8)

167/970 (17.2)

2.63 (1.38-5.00)

8.8 (4.6-14.9)

9.9 (4.3-21.1)

1.11 (1.02-1.19)

607/661 (91.8)

54/661 (8.2)

1 [Reference]

Bacteria

91/99 (91.9)

8/99 (8.1)

0.92 (0.42-2.03)

Virus

666/810 (82.2)

144/810 (17.8)

2.81 (1.98-3.99)

.06

ED location

Distance between home and ED,
median (IQR), kmb
Infectious agent

.003
.01

c

Negative
Isolated organism

Virus/bacteria codetection

26/30 (86.7)

4/30 (13.3)

2.42 (0.78-7.50)

Parasitesd

15/19 (78.9)

4/19 (21.1)

3.89 (1.18-12.81)

None (0)

1062/1114 (95.3)

52/1114 (4.7)

1 [Reference]

Mild to moderate (1-4)

524/681 (76.9)

157/681 (23.1)

10.00
(6.92-14.45)

Severe (5-8)

13/40 (32.5)

27/40 (67.5)

69.54
(31.21-154.94)

1119/1312 (85.3)

193/1312 (14.7)

1 [Reference]

<.001

Clinical Dehydration Scale score

<.001

Oral ondansetron administered
in the EDe
No
Yes
No. of diarrhea episodes
in 24 h preceding index
ED visit, median (IQR)b

487/534 (91.2)

47/534 (8.8)

0.43 (0.31-0.61)

5.0 (4.0-8.0)

7.0 (4.0-10.0)

1.41 (1.24-1.61)

<.001

<.001

Duration of diarrhea, h
1 to <96

1445/1648 (87.7)

203/1648 (12.3)

1 [Reference]

96 to <120

76/96 (79.2)

20/96 (20.8)

1.49 (0.87-2.55)

≥120

68/83 (81.9)

15/83 (18.1)

1.24 (0.68-2.25)

2.0 (0.0-5.0)

4.0 (2.0-8.0)

1.65 (1.44-1.89)

No. of vomiting episodes
in 24 h preceding index
ED visit, median (IQR)b

Abbreviations: ED, emergency department; IQR,
interquartile range; IV, intravenous; OR, odds ratio;
PECARN, Pediatric Emergency Care Applied Research
Network; PERC, Pediatric Emergency
Research Canada.
a

ORs and CIs compare the odds of receiving IV fluids
for each group vs the reference category or for an
increase of 5 vomit or diarrhea episodes, or for a
10-km increase in geodetic distance between a
patient’s residence and the hospital zip code. A
random effect of enrolling clinical site is included in
all models. Models are otherwise unadjusted.

b

Seven participants did not report a zip code; 6 did
not report a number of vomiting or diarrhea episodes
in 24 hours preceding the index ED visit.

c

Includes participants in whom stool testing was
performed and results were available.

d

Parasites alone were detected in 12 participants;
parasite and virus or parasite and bacterium were
codetected in 7 participants.

e

Excluding oral ondansetron given within 30 minutes
of or after ordering IV rehydration.

f

Fever was defined as rectal temperature ⱖ38.0 °C in
the PERC cohort; tactile fever or temperature ⱖ38.0
°C adjusted to rectal temperature in the PECARN
cohort during the current illness, either at home or in
the ED.

.30

<.001

Duration of vomiting, h
No vomiting

417/437 (95.4)

20/437 (4.6)

1 [Reference]

1 to <24

351/405 (86.7)

54/405 (13.3)

2.94 (1.71-5.04)

24 to <48

311/367 (84.7)

56/367 (15.3)

3.61 (2.10-6.22)

≥48

403/504 (80.0)

101/504 (20.0)

4.79 (2.89-7.96)

<.001

Preceding health care
practitioner visit
No

1393/1556 (89.5)

163/1556 (10.5)

1 [Reference]

Yes, but no IV rehydration

197/261 (75.5)

64/261 (24.5)

2.43 (1.73-3.42)

Yes, with IV rehydration

5/16 (31.3)

11/16 (68.8)

15.27
(5.14-45.39)

<.001

Feverf
No

783/861 (90.9)

78/861 (9.1)

1 [Reference]

Yes

820/981 (83.6)

161/981 (16.4)

1.86 (1.39-2.50)

<.001
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Table 2. Bivariate Analysis of Index Emergency Department Variables Associated With Hospitalization
Admission to hospital, No./total No. (%)

Model results

No (n = 1775)

Yes (n = 67)

Unadjusted OR (95%
CI)a

Boys

971/1005 (96.6)

34/1005 (3.4)

1 [Reference]

Girls

804/837 (96.1)

33/837 (3.9)

1.17 (0.72-1.92)

Variable

P valueb

Sex
.52

Age group, mo
3.0 to <12.0

583/611 (95.4)

28/611 (4.6)

1 [Reference]

12.0 to <24.0

655/678 (96.6)

23/678 (3.4)

0.79 (0.45-1.39)

24.0 to <36.0

326/337 (96.7)

11/337 (3.3)

0.70 (0.34-1.44)

36.0 to <48.0

211/216 (97.7)

5/216 (2.3)

0.50 (0.19-1.32)

Canada

854/876 (97.5)

22/876 (2.5)

1 [Reference]

US

921/966 (95.3)

45/966 (4.7)

1.81 (0.80-4.12)

8.8 (4.5-15.2)

11.7 (5.1-31.0)

1.23 (1.12-1.36)

646/661 (97.7)

15/661 (2.3)

1 [Reference]

Bacteria

97/99 (98.0)

2/99 (2.0)

0.88 (0.19-3.93)

Virus

765/810 (94.4)

45/810 (5.6)

2.89 (1.58-5.31)

.48

ED location

Distance from home to ED, median
(IQR), kmb
Infectious agent

.15
<.001

c

Negative
Isolated organism

Virus/bacteria codetection

29/30 (96.7)

1/30 (3.3)

1.89 (0.23-15.30)

Parasitesd

19/19 (100.0)

0/19

NA

None (0)

1105/1114 (99.2)

9/1114 (0.8)

1 [Reference]

Mild to moderate (1-4)

633/681 (93.0)

48/681 (7.0)

11.84 (5.67-24.71)

Severe (5-8)

30/40 (75.0)

10/40 (25.0)

53.45
(19.10-149.57)

.004

Clinical Dehydration Scale score

<.001

Oral ondansetron administered in the
EDe
No

1253/1308 (95.8)

55/1308 (4.2)

1 [Reference]

Yes

522/534 (97.8)

12/534 (2.2)

0.47 (0.25-0.89)

5.0 (4.0-8.0)

8.0 (4.0-15.0)

1.67 (1.39-2.01)

No. of diarrhea episodes in 24 h
preceding index ED visit, median
(IQR)b

.02

Abbreviations: ED, emergency department; IV,
intravenous; NA, not available; OR, odds ratio;
PECARN, Pediatric Emergency Care Applied Research
Network; PERC, Pediatric Emergency
Research Canada.
a

ORs and CIs compare the odds of being admitted for
each group vs the reference category or for an
increase of 5 vomit or diarrhea episodes or for a
10-km increase in geodetic distance between a
patient’s residence and the hospital zip code. A
random effect of enrolling clinical site is included in
all models. Models are otherwise unadjusted.

b

Five participants did not report a zip code; 2 did not
report a number of vomiting or diarrhea episodes in
24 hours preceding the index ED visit.

c

Includes participants in whom stool testing was
performed and results were available; patients with
isolated parasites excluded from estimation of ORs
due to low numbers.

d

Parasites alone were detected in 12 participants;
parasite and virus or parasite and bacteria were
codetected in 7 participants.

e

Excluding oral ondansetron given within 30 minutes
or after ordering IV fluid.

f

Fever was defined as rectal temperature ⱖ38.0 °C in
the PERC cohort; tactile fever or temperature ⱖ38.0
°C adjusted to rectal temperature in the PECARN
cohort during the current illness, either at home or in
the ED.

<.001

Duration of diarrhea, h
1 to <96

1593/1648 (96.7)

55/1648 (3.3)

1 [Reference]

96 to <120

88/96 (91.7)

8/96 (8.3)

2.21 (0.99-4.94)

≥120

79/83 (95.2)

4/83 (4.8)

1.28 (0.44-3.70)

2.0 (0.0-5.0)

4.0 (1.0-8.0)

1.50 (1.25-1.81)

No. of vomiting episodes in 24 h
preceding index ED visit, median
(IQR)b

.15

<.001

Duration of vomiting, h
No vomiting

430/437 (98.4)

7/437 (1.6)

1 [Reference]

1 to <24

388/405 (95.8)

17/405 (4.2)

2.62 (1.07-6.43)

24 to <48

354/367 (96.5)

13/367 (3.5)

2.33 (0.91-5.99)

≥48

478/504 (94.8)

26/504 (5.2)

3.21 (1.37-7.56)

.06

Preceding health care practitioner
visit
No

1511/1556 (97.1)

45/1556 (2.9)

1 [Reference]

Yes, but no IV rehydration

243/261 (93.1)

18/261 (6.9)

2.21 (1.24-3.94)

Yes, with IV rehydration

12/16 (75.0)

4/16 (25.0)

10.26 (3.11-33.86)

No

840/861 (97.6)

21/861 (2.4)

1 [Reference]

Yes

935/981 (95.3)

46/981 (4.7)

1.93 (1.14-3.28)

<.001

Feverf
.02
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Discussion
In this planned secondary analysis of the PERC and PECARN trials of oral probiotics in children with
AGE-associated diarrhea, we identified independent variables associated with intravenous
rehydration and hospitalization. Significant variables included more severe dehydration, care in the
US, greater travel distance to the ED, and more vomiting episodes in the 24 hours preceding the ED
visit. Oral ondansetron followed by ORT reduced the odds of receiving intravenous rehydration and
hospitalization, underlying its importance in the majority of children with AGE.4,6,30 These findings
can inform quality improvement initiatives to improve outcomes in at-risk children.
After adjustment for clinical characteristics, intravenous rehydration and hospitalization rates
were much higher in the US. This finding is most likely explained by a previously characterized
difference in willingness to initiate ORT as first-line therapy in children with moderate dehydration
between emergency providers in Canada (76% willing) and the US (46% willing).31 Differences
between Canada and the US, such as perception of medicolegal risks, training, hospital budgets, and
parental expectations, have been highlighted as possible explanations to explain greater use of
diagnostic imaging in US EDs.32 Some of these explanations may apply to intravenous rehydration
and hospitalization. For example, the parents of young children in the US, when given the
opportunity to make an informed decision, often opt for intravenous over ORT.9 Despite country
differences, there was no association of site with outcomes. The study protocols standardized the
treatment strategies and focused on the promotion of ORT, supported by ondansetron, as required.
We did not explore variation in care over time, but as no major changes occurred in the

Figure 2. Adjusted Odds Ratios (ORs) From Multivariable Models of Variables Associated With Intravenous (IV) Rehydration
Study

OR (95% CI)

Sex, girl vs boy

1.02 (0.72-1.43)

Decreased odds

.92

Age, 12 to <24 mo (vs 3 to <12 mo)

1.50 (0.98-2.31)

.06

Age, 24 to <36 mo (vs 3 to <12 mo)

1.39 (0.83-2.33)

.21

Age, 36 to <48 mo (vs 3 to <12 mo)

1.73 (0.97-3.08)

.06

Emergency department location: US (vs Canada)

6.76 (3.15-14.49)

<.001

Distance between home and emergency department: per 10 km

1.01 (0.91-1.13)

.79

Infectious agent: isolated bacteria (vs negative)

0.76 (0.30-1.90)

.56

Infectious agent: isolated virus (vs negative)

1.80 (1.16-2.79)

.009

Infectious agent: virus/bacteria codetection (vs negative)

1.83 (0.49-6.85)

.37

Infectious agent: other (vs negative)

1.71 (0.34-8.63)

.52

Clinical dehydration scale: mild to moderate (1-4) (vs none)

8.73 (5.81-13.13)

<.001

Clinical dehydration scale: severe (5-8) (vs none)

34.15 (13.45-86.73)

<.001

Oral ondansetron in ED (vs no)

0.21 (0.13-0.32)

<.001

Number of diarrhea episodes in preceding 24 h (per 5 episodes)

1.18 (0.99-1.39)

.06

Duration of diarrhea: 96 to <121 h (vs <96 h)

1.23 (0.61-2.48)

.56

Duration of diarrhea: 121 h or more (vs <96 h)

0.72 (0.35-1.51)

.39

Number of vomiting episodes in preceding 24 h (per 5 episodes)

1.66 (1.39-1.99)

<.001

Duration of vomiting: 1 to <24 h (vs no vomiting)

1.92 (1.01-3.66)

.05

Duration of vomiting: 25 to <48 h (vs no vomiting)

2.30 (1.21-4.38)

.01

Duration of vomiting: 48 h or more (vs no vomiting)

2.53 (1.39-4.61)

.002

Preceding health care provider visit (vs no)

1.82 (1.20-2.77)

.005

Preceding health care provider visit with no IV rehydration

1.69 (1.09-2.61)

.02

Preceding health care provider visit with IV rehydration

4.55 (1.32-15.72)

.02

Fever (vs no)

1.43 (1.00-2.03)

.05
0.01

0.1

Increased odds

1

10

P value

100

OR (95% CI)

Estimates for infectious agent are from a secondary model using 1489 participants for
whom stool testing results were available. The “other” category included isolated
parasites in the absence of other infectious agents of interest (n = 11) and parasite or
virus codetection (n = 7). Estimates for a preceding health care practitioner visit with no
IV rehydration and a preceding health care practitioner visit with IV rehydration are from

a secondary model using 1690 participants with information about prior health care
practitioner visits. All other estimates are from a model using 1692 participants in which
the largest variance inflation factor was 1.28 and intraclass correlation within sites was
0.09. ED indicates emergency department.
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recommended care of children with AGE,5 there is no reason to believe there was any variation in
care over time.
The proportion of children receiving intravenous rehydration in our study was lower than
reported in large retrospective studies (n = 3508 [13%] in Canada33 and n = 30 519 [26%] in the
US16). Although it is encouraging to see lower overall numbers, it should be noted that a leading
driver of intravenous rehydration, vomiting,34 was absent in 30% of our participants, with 51%
having fewer than 3 episodes. This may have explained the low proportion of participants that
received ondansetron in our study (28.9%), as ondansetron is indicated for dehydration and
frequent and recent vomiting. Importantly, among participants who received intravenous
rehydration, 89% were not severely dehydrated, suggesting that intravenous rehydration may be
overused in pediatric EDs.
Our results are consistent with evidence that frequent vomiting is associated with intravenous
rehydration.34 Although gastroenteritis severity is often characterized by the frequency and duration
of diarrhea, our multivariable models showed that dehydration severity, quantified using the CDS,
was more strongly associated with both intravenous rehydration and hospitalization. Although this
association makes intuitive sense, clinical and laboratory assessments of dehydration in children are
inaccurate.7 Cognitive bias may partly explain the strong association between higher CDS scores and
intravenous rehydration. Sunken eyes and dry mucous membranes are both components of the CDS
and have long been held as useful clinical signs of dehydration.35 Clinical identification of these
factors may have driven intravenous rehydration, because subjective clinical measures often
overestimate the degree of dehydration,36 leading to potentially unnecessary intravenous
rehydration. Thus, in high-income countries, otherwise healthy children, even those with high CDS
scores, in the absence of circulatory compromise should initially undergo a trial of ORT.

Figure 3. Adjusted Odds Ratios (ORs) From Multivariable Models of Variables Associated With Hospitalization From the Emergency Department (ED) Index Visit
Study

OR (95% CI)

Sex, girl vs boy

1.36 (0.77-2.40)
0.67 (0.34-1.31)
0.90 (0.40-2.03)
0.30 (0.10-0.97)
3.37 (1.36-8.40)
1.20 (1.06-1.36)
0.54 (0.08-3.46)
1.86 (0.88-3.94)
1.38 (0.15-12.95)
11.10 (5.05-24.38)
23.55 (7.09-78.25)
0.44 (0.21-0.89)
1.34 (1.07-1.68)
2.23 (0.82-6.09)
1.18 (0.36-3.81)
1.41 (1.13-1.77)
1.48 (0.54-4.10)
1.26 (0.43-3.71)
1.22 (0.45-3.28)
1.10 (0.55-2.18)
0.96 (0.46-2.02)
2.70 (0.64-11.38)
1.65 (0.90-3.03)

Age, 12 to <24 mo (vs 3 to <12 mo)
Age, 24 to <36 mo (vs 3 to <12 mo)
Age, 36 to <48 mo (vs 3 to <12 mo)
Emergency department location: US (vs Canada)
Distance between home and emergency department: per 10 km
Infectious agent: isolated bacteria (vs negative)
Infectious agent: isolated virus (vs negative)
Infectious agent: virus/bacteria codetection (vs negative)
Clinical dehydration scale: mild to moderate (1-4) (vs none)
Clinical dehydration scale: severe (5-8) (vs none)
Oral ondansetron in ED (vs no)
Number of diarrhea episodes in preceding 24 h (per 5 episodes)
Duration of diarrhea: 96 to <121 h (vs <96 h)
Duration of diarrhea: 121 h or more (vs <96 h)
Number of vomiting episodes in preceding 24 h (per 5 episodes)
Duration of vomiting: 1 to <24 h (vs no vomiting)
Duration of vomiting: 25 to <48 h (vs no vomiting)
Duration of vomiting: 48 h or more (vs no vomiting)
Preceding health care provider visit (vs no)
Preceding health care provider visit with no IV rehydration
Preceding health care provider visit with IV rehydration
Fever (vs no)

Decreased odds

Increased odds

P value
.28
.24
.81
.04
.009
.004
.51
.11
.78
<.001
<.001
.02
.01
.12
.79
.003
.45
.68
.70
.79
.92
.18
.11

0.01

0.1

1

10

100

OR (95% CI)

Estimates for infectious agent are from a secondary model using 1471 participants for
whom stool testing results were available and excluding those with parasites. Estimates
for a preceding health care practitioner visit with no intravenous (IV) rehydration and a
preceding health care practitioner visit with IV rehydration are from a secondary model

using 1690 participants with information about prior visits. All other estimates are from
a model using 1692 participants in which the largest variance inflation factor was 1.28.
Intraclass correlation within sites was 0.09.
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One approach to reduce the use of intravenous rehydration is oral ondansetron followed by a
trial of ORT.37 Although clinical trials have consistently demonstrated benefit, database studies,
which lack detailed clinical characteristics and timelines, have reported less positive results.38 Our
study, which included timelines related to ondansetron administration, route, and timing of orders
for intravenous rehydration, enabled us to ensure that oral ondansetron was administered a
minimum of 30 minutes before the order for intravenous rehydration, thereby ensuring it was given
and followed by ORT. This is an important concept, as one can reach incorrect conclusions when such
an approach is not incorporated into analyses, because in some settings, oral ondansetron and
intravenous rehydration are ordered simultaneously. Our finding associating oral ondansetron with a
reduction in intravenous rehydration and hospitalization suggest that strategies promoting the
appropriate use of oral ondansetron in children with AGE and nonsevere dehydration are crucial to
accruing its benefits.39
Unscheduled revisit rates for children with AGE range from 7% to 18%15,38,40 and are associated
with absence of a primary care provider, higher serum bicarbonate,40 greater frequency of vomiting
and diarrhea,15 and administration of intravenous rehydration in the ED.15 Similarly, we found that
prior ED visits, particularly those associated with intravenous rehydration, were associated with
intravenous rehydration at the enrollment ED visit. These findings highlight the importance of
administering intravenous rehydration based on presenting clinical features rather than previous
therapies. This approach is important because caregivers of children who received intravenous
rehydration are less likely to comply with ORT recommendations.41
Consistent with previous reports,38,42,43 the proportion of children with AGE admitted to the
hospital was low (3.6%). Our data suggest that hospitalization was associated with more severe
dehydration and care in the US. The latter association may reflect previously published differences in
health care resource utilization between Canada and the US in children with AGE.31 Although we did
not quantify volume of oral fluids consumed or fluid losses in the ED, a higher CDS score is
independently associated with ORT failure,44 which may have influenced the decision for
hospitalization. Consistent with previous reports,45,46 we found oral ondansetron to be associated
with a lower odds of hospitalization, most likely through the reduction in intravenous rehydration.
Thus, promoting oral ondansetron and a trial of ORT in the ED for children with nonsevere
dehydration may decrease the risk of intravenous rehydration and demonstrate a strategy that
caregivers can continue post–ED discharge.

Limitations
Our study has several limitations. We enrolled children presenting to tertiary care pediatric centers in
high-income countries, and only a small proportion were severely dehydrated. Although baseline
characteristics, such as socioeconomic status, would have helped generalize our findings, we
unfortunately did not collect this information in both studies in a manner that could be integrated
into a joint analysis. Therefore, our results may not be applicable to children presenting for care in
rural or low-resource settings where geographic, economic, and etiologic factors may influence the
need for intravenous rehydration. As this was a secondary analysis, our data may not be generalizable
to patients outside the trial’s eligibility criteria. Furthermore, we were unable to ascertain the role of
other potential risk factors, including insurance status, provider experience, or the ability of the child
and caregiver to perform ORT. The 2 trials were conducted in countries with different populations
and health care systems. An important protocol difference that could have affected results was
maximal symptom duration prior to enrollment between PERC (72 hours) and PECARN (7 days). For
this reason, country and duration of gastrointestinal symptoms at the index visit were included in
the models to address these potential limitations. Finally, we did not describe parental expectations,
a potentially influential factor in clinical decision-making. Evidence suggests that parental
expectations often contradict clinical practice guidelines and reflect a preference for intravenous
rehydration.9,41
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Conclusions
In this study of children with AGE and minimal dehydration, independent variables associated with
intravenous rehydration and hospitalization included greater dehydration, care in the US, greater
travel distance to the ED, and more vomiting episodes in the 24 hours preceding the ED visit. Oral
ondansetron followed by ORT was associated with a lower odds of both intravenous rehydration and
hospitalization. Cost- and time-saving strategies focused on promoting successful integration of ORT
and oral ondansetron into ED care for most children with AGE have the potential to reduce
intravenous rehydration and hospitalizations rates.
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